Dianthus (DNTH) | Financial Analysis & Statements
Dianthus Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
284.0K
Operating Income
-69.5M
-24,486.27%
Net Income
-64.4M
-22,687.32%
EPS (Diluted)
$-1.43
Balance Sheet Metrics
Total Assets
530.9M
Total Liabilities
37.5M
Shareholders Equity
493.4M
Debt to Equity
0.08
Cash Flow Metrics
Operating Cash Flow
-47.0M
Free Cash Flow
-47.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dianthus Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.0M | 6.2M | 2.8M | 6.4M | 1.5M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 145.6M | 83.1M | 32.8M | 29.4M | 12.6M |
| Selling, General & Administrative | 34.3M | 25.0M | 18.2M | 6.7M | 2.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 180.0M | 108.1M | 51.0M | 36.1M | 14.6M |
| Operating Income | -177.9M | -101.9M | -48.2M | -29.7M | -13.1M |
| Operating Margin % | -8,739.3% | -1,633.7% | -1,704.7% | -462.9% | -886.6% |
| Non-Operating Items | |||||
| Interest Income | 16.1M | 17.4M | 4.8M | 1.1M | 3.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -523.0K | -470.0K | -145.0K | 84.0K | -26.0K |
| Pre-tax Income | -162.3M | -85.0M | -43.6M | -28.5M | -13.1M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -162.3M | -85.0M | -43.6M | -28.5M | -13.1M |
| Net Margin % | -7,973.3% | -1,362.8% | -1,541.2% | -443.8% | -888.1% |
| Key Metrics | |||||
| EBITDA | -178.0M | -101.5M | -47.7M | -29.7M | -13.1M |
| EPS (Basic) | - | $-2.55 | $-8.45 | $-1.92 | $-0.88 |
| EPS (Diluted) | - | $-2.55 | $-8.45 | $-1.92 | $-0.88 |
| Basic Shares Outstanding | - | 33313849 | 5153423 | 14817700 | 14817700 |
| Diluted Shares Outstanding | - | 33313849 | 5153423 | 14817700 | 14817700 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Dianthus Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 51.1M | 22.8M | 132.3M | 15.4M | 7.6M |
| Short-term Investments | 353.2M | 252.4M | 41.4M | 60.1M | 0 |
| Accounts Receivable | 52.0K | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 86.0K | 1.1M | 504.0K | 53.0K | 10.0K |
| Total Current Assets | 409.4M | 280.9M | 177.5M | 82.0M | 9.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.3M | 1.6M | 615.0K | 814.0K | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 9.7M | 9.6M | 1.2M | 121.0K | 30.0K |
| Total Non-Current Assets | 121.5M | 93.1M | 2.0M | 1.1M | 63.0K |
| Total Assets | 530.9M | 374.0M | 179.4M | 83.1M | 9.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.7M | 4.6M | 2.6M | 1.2M | 1.4M |
| Short-term Debt | 367.0K | 320.0K | 417.0K | 350.0K | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 30.7M | 18.5M | 9.6M | 8.2M | 5.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.0M | 1.2M | 168.0K | 438.0K | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 6.8M | 3.1M | 904.0K | 1.2M | 21.3M |
| Total Liabilities | 37.5M | 21.5M | 10.5M | 9.5M | 26.7M |
| Equity | |||||
| Common Stock | 43.0K | 31.0K | 15.0K | 0 | 0 |
| Retained Earnings | -336.7M | -174.4M | -89.4M | -45.9M | -17.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 493.4M | 352.5M | 168.9M | 73.7M | -17.2M |
| Key Metrics | |||||
| Total Debt | 1.4M | 1.5M | 585.0K | 788.0K | 0 |
| Working Capital | 378.7M | 262.5M | 167.8M | 73.8M | 4.0M |
Balance Sheet Composition
Dianthus Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -162.3M | -85.0M | -43.6M | -28.5M | -13.1M |
| Depreciation & Amortization | 428.0K | 412.0K | 355.0K | 147.0K | 0 |
| Stock-Based Compensation | 22.8M | 12.9M | 2.9M | 1.5M | 63.0K |
| Working Capital Changes | 17.0M | 1.2M | 4.7M | -1.0M | 3.4M |
| Operating Cash Flow | -122.2M | -70.6M | -35.6M | -27.8M | -9.6M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -435.0M | -413.7M | -57.4M | -61.7M | 0 |
| Investment Sales | 312.4M | 127.0M | 77.8M | 2.0M | 0 |
| Investing Cash Flow | -122.6M | -286.7M | 20.4M | -59.7M | 0 |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 377.0K | 0 | - |
| Debt Repayment | - | 0 | -377.0K | 0 | - |
| Financing Cash Flow | 271.9M | 254.5M | 133.6M | 96.7M | 14.9M |
| Free Cash Flow | -129.3M | -78.3M | -37.0M | -29.2M | -9.9M |
| Net Change in Cash | 27.1M | -102.7M | 118.4M | 9.2M | 5.3M |
Cash Flow Trend
Dianthus Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
3.30
Forward P/E
-17.56
Price to Book
7.87
Price to Sales
2,402.06
PEG Ratio
0.04
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-24,486.27%
Return on Equity
-38.38%
Return on Assets
-24.58%
Financial Health
Current Ratio
13.32
Debt to Equity
0.28
Beta
0.21
Per Share Data
EPS (TTM)
$-4.20
Book Value per Share
$11.42
Revenue per Share
$0.05
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DNTH | 4.9B | 3.30 | 7.87 | -38.38% | 0.00% | 0.28 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






